← Back to Home

Services

Precision immunogenicity for every patient.

We serve life science organizations building the next generation of immunotherapies as well as individual patients exploring personalized therapeutic options today.

For Biopharma & Life Sciences

The partner of choice for immunogenicity prediction

Areca Bio serves as the foundational prediction partner for biopharma and life sciences companies running cancer vaccine programs. Our platform integrates seamlessly with existing genomic workflows to deliver superior neoantigen prioritization — across oncology indications and beyond.

We partner at the earliest stages of program design through clinical trial execution, offering co-development arrangements, licensing pathways, and ongoing scientific collaboration.

Explore Partnership

What We Offer

Neoantigen immunogenicity prediction for tumor types across solid cancers
Co-development partnerships for cancer vaccine clinical programs
Computational analysis of phase I/II trial cohorts
Ongoing research collaboration and publication rights

Our Approach

Personalized neoantigen analysis from tumor biopsy genomic data
Consultation with our scientific team on immunogenic targets
Coordination with your treating oncologist and care team
Compassionate use and expanded access program navigation
Clear, plain-language reporting of prediction results
Ongoing support through the therapeutic design process

For Patients

The path to your most personalized cancer treatment

We believe every cancer patient deserves access to the most precise immunotherapy available. Areca Bio works directly with patients and their care teams to apply our prediction engine to their tumor genomic data — identifying the most immunogenic targets for personalized vaccine design.

Our team guides patients through compassionate use pathways and coordinates with treating oncologists to ensure results are actionable, understandable, and integrated into the broader treatment plan.

Reach Out

Ready to get started?

Get in Touch